Viewing Study NCT00114634



Ignite Creation Date: 2024-05-05 @ 11:42 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00114634
Status: COMPLETED
Last Update Posted: 2016-01-29
First Post: 2005-06-15

Brief Title: Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD
Organization: National Institutes of Health Clinical Center CC

Study Overview

Official Title: Short-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome
Status: COMPLETED
Status Verified Date: 2015-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This 10-week study will evaluate and compare behavior changes in children with Smith-Lemli-Opitz syndrome SLOS who are taking cholesterol supplementation versus those who are not on cholesterol supplementation SLOS is a genetic disorder that affects the development of children both before and after birth An enzyme deficiency in these children results in low levels of cholesterol which can cause a variety of birth defects and behavioral problems Typical abnormal physical features of patients include a small head drooping eyelids small upturned nose small chin cleft palate heart defects and extra fingers or toes

Children between 5 and 17 with mild SLOS who do not have a history of egg allergy or intolerance may be eligible for this study Candidates are screened with a questionnaire about the patients age genotype if known sterol levels symptoms current treatment and medical history

Children participate in two 2-week study phases Between the study phases the children will take 150 mgkg daily of a cholesterol preparation typically used to supplement cholesterol in patients in SLOS studies at NIH In the study phases the participants are randomly assigned to take either egg yolk or an egg yolk substitute such as Egg Beaters that does not contain cholesterol The study is done at the participants home and the cholesterol supplementation and eggegg substitute are sent to the home each day with instructions on how to take them

The caretakers can stop the study phases after four days if behavior problems occur

The childrens caretakers fill out a standard behavioral questionnaire the Aberrant Behavior Checklist The questionnaire is designed to assess the effects of treatment in mentally impaired persons
Detailed Description: Smith-Lemli- Opitz syndrome SLOS is an autosomal recessive genetic condition caused by a deficiency of the enzyme 3beta-hydroxysterol delta7- reductase DHCR7 DHCR7 is the final enzyme in the sterol synthetic pathway and converts 7- dehydrocholesterol 7DHC to cholesterol This results in low cholesterol and elevated 7DHC levels SLOS has a wide phenotypic spectrum Mildly affected individuals may have subtle dysmorphic features along with learning and behavioral disabilities Typical clinical manifestations include microcephaly ptosis anteversion of the nostrils micrognathia high arched or cleft palate congenital heart defects clinodactyly post- axial polydactyly and 2-3 toe syndactyly More severely affected individuals have multiple congenital anomalies may be miscarried stillborn or die within the first few weeks of life

Dietary cholesterol supplementation in children with SLOS is reported to improve behavior growth and nutritional status Based upon observational studies the behavioral changes reported with dietary cholesterol supplementation occur rapidly and appear to be reversible Parental reports of improved behavior could be influenced by a placebo effect Thus we are proposing a blinded study to compare behavioral changes while the patient is on cholesterol supplementation egg yolk versus no cholesterol supplementation egg substitute

The objectives of this study are

1 To quantitatively evaluate behavior in a blinded study of SLOS children on and off dietary cholesterol supplementation
2 To quantitatively evaluate behavior in SLOS children treated with egg yolk compared to synthetic dietary cholesterol supplementation

Completed study has been published Tierney E Conley SK Goodwin H Porter FD 2010 Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz Syndrome Am J Med Genet Part A 152A 91-95 PMID 20014133

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
05-CH-0168 OTHER NIH CC None